<![CDATA[Weighing Mutation Status and Fitness in Frontline AML Regimen Choice]]>

<![CDATA[Shifting the Paradigm: Evidence, Earlier Use, and Sequencing of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma]]>

<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>

Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients

Conditions : Bone Marrow Transplantation; AML Sponsors : Yasmin medhat munir Mohamed Not yet recruiting

Epigenomic Analysis Reveals 16 New AML Subgroups and Drug Sensitivities

A chromatin-based study of 1,563 AML samples identifies novel epigenomic subgroups that enhance prognostic accuracy and uncover unexpected t

Epigenomic Analysis Uncovers New AML Subgroups and Drug Sensitivities

New chromatin‑based analysis of 1,563 AML samples reveals 16 epigenomic subgroups that improve prognostic accuracy and highlight unexpected

Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes

Clonal hematopoiesis (CH) is the age-related expansion of mutated hematopoietic stem cells without hematologic abnormalities. In patients wi